OncoSec Medical Announces Positive Interim Data from Phase 2 Metastatic Melanoma Study

By: Benzinga
OncoSec Medical (OTC: ONCS ) today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal…
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.